Bayesian clinical trials in action
暂无分享,去创建一个
[1] M. Tighiouart,et al. Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials , 2010 .
[2] S. Fienberg. Does it make sense to be an "objective Bayesian"? (comment on articles by Berger and by Goldstein) , 2006 .
[3] J. Berger. The case for objective Bayesian analysis , 2006 .
[4] D. Berry. Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.
[5] A W Kelman,et al. Population Pharmacokinetics Theory and Clinical Application , 1986, Clinical pharmacokinetics.
[6] S. Goodman. Introduction to Bayesian methods I: measuring the strength of evidence , 2005, Clinical trials.
[7] Peter D. Hoff,et al. A First Course in Bayesian Statistical Methods , 2009 .
[8] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Lucila Ohno-Machado,et al. Exploration of a Bayesian Updating Tool to Provide Real-Time Safety Monitoring for New Medical Devices , 2005, AMIA.
[10] R. Wolpert,et al. Likelihood Principle , 2022, The SAGE Encyclopedia of Research Design.
[11] Runo,et al. GENERALIZED MOMENT THEORY AND BAYESIAN ROBUSTNESS ANALYSIS FOR HIERARCHICAL MIXTURE MODELS , 2005 .
[12] Stephen M. Stigler,et al. The history of statistics in 1933 , 1996 .
[13] D. Berry. Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.
[14] B. Efron. Bayesians, Frequentists, and Scientists , 2005 .
[15] Diane D. Liu,et al. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center , 2009, Clinical trials.
[16] T. Bayes. An essay towards solving a problem in the doctrine of chances , 2003 .
[17] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[18] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[19] José M. Bernardo,et al. Bayesian Reference Analysis , 2005 .
[20] D. Berry. Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .
[21] D. Berry. Adaptive trial design. , 2007, Clinical advances in hematology & oncology : H&O.
[22] Andrew Thomas,et al. The BUGS project: Evolution, critique and future directions , 2009, Statistics in medicine.
[23] Adrian F. M. Smith,et al. Sampling-Based Approaches to Calculating Marginal Densities , 1990 .
[24] M A Schneiderman,et al. Historical and methodological developments in clinical trials at the National Cancer Institute. , 1990, Statistics in medicine.
[25] Mourad Tighiouart,et al. Translation of innovative designs into phase I trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Donald Geman,et al. Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images , 1984 .
[27] J. Bernardo. The Concept of Exchangeability and its Applications , 2001 .
[28] P. Meier. Jerome Cornfield and the methodology of clinical trials. , 1981, Controlled clinical trials.
[29] P. Thall,et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome , 2008, Leukemia.
[30] Scott M Berry,et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[32] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[33] D G Altman,et al. Transfer of technology from statistical journals to the biomedical literature. Past trends and future predictions. , 1994, JAMA.
[34] G. Casella,et al. Explaining the Gibbs Sampler , 1992 .
[35] T. Louis. Introduction to Bayesian methods II: fundamental concepts , 2005, Clinical trials.
[36] Andrew P Grieve,et al. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel , 2007, Pharmaceutical statistics.
[37] J. Ware,et al. Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute. , 1990, Statistics in medicine.
[38] J. Berger. Could Fisher, Jeffreys and Neyman Have Agreed on Testing? , 2003 .
[39] Ming-Dauh Wang,et al. Bayesian predictive approach to interim monitoring in clinical trials , 2006, Statistics in medicine.
[40] Elja Arjas,et al. On Future Directions in Statistical Methodologies – Some Speculations , 2011 .
[41] Pierpaolo Brutti,et al. Robust Bayesian sample size determination in clinical trials , 2008, Statistics in medicine.
[42] L B Sheiner,et al. Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.
[43] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[44] Sylvie Chevret,et al. Bayesian adaptive clinical trials: a dream for statisticians only? , 2012, Statistics in medicine.
[45] 김성문,et al. [해외 대학 연구센터 소개] Rutgers, The State University of New Jersey , 2012 .
[46] Robert J. Bauer,et al. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.
[47] James O. Berger,et al. The interplay of Bayesian and frequentist analysis , 2004 .
[48] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[49] Michael Goldstein,et al. Subjective Bayesian Analysis: Principles and Practice , 2006 .
[50] F. Ederer. Jerome Cornfield's contributions to the conduct of clinical trials. , 1982, Biometrics.
[51] Bradley P. Carlin,et al. Bayesian Adaptive Methods for Clinical Trials , 2010 .
[52] Edward S. Kim,et al. Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.
[53] Say-Beng Tan,et al. Where's the utility in Bayesian data-monitoring of clinical trials? , 2005, Clinical trials.
[54] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[55] Anthony O'Hagan,et al. Bayesian Robustness Modelling of Location and Scale Parameters , 2011 .
[56] D. Ashby. Bayesian statistics in medicine: a 25 year review , 2006, Statistics in medicine.
[57] K R Abrams,et al. Bayesian methods in meta-analysis and evidence synthesis. , 2001, Statistical methods in medical research.
[58] Stephen M. Stigler,et al. Thomas Bayes's Bayesian Inference , 1982 .
[59] R. Little. Calibrated Bayes , 2006 .
[60] G. Apostolakis,et al. Exploration of a Bayesian Updating Methodology to Monitor the Safety of Interventional Cardiovascular Procedures , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[61] Donald A Berry,et al. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis , 2005, Clinical trials.